Loading...
Header Logo
Keywords
Last Name
Institution

KAPIL BHALLA

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the ß-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 Apr 09; 135(15):1255-1269. PMID: 32068780.
      View in: PubMed
    2. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. Clin Cancer Res. 2020 03 15; 26(6):1531. PMID: 32169966.
      View in: PubMed
    3. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 Jun; 34(6):1588-1598. PMID: 31862959.
      View in: PubMed
    4. Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. 2019 10; 43(10):1429-1437. PMID: 31261288.
      View in: PubMed
    5. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229. PMID: 31400013.
      View in: PubMed
    6. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K. Editor's Note: Cotreatment with STI-571 Enhances Tumor Necrosis Factor a-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)-induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells. Clin Cancer Res. 2019 Jul 01; 25(13):4195. PMID: 31263034.
      View in: PubMed
    7. Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019 06 19; 11(497). PMID: 31217338.
      View in: PubMed
    8. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73. PMID: 31023702.
      View in: PubMed
    9. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4. PMID: 30647404.
      View in: PubMed
    10. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear ß-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386. PMID: 30575820.
      View in: PubMed
    11. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139.
      View in: PubMed
    12. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431.
      View in: PubMed
    13. DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G. Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes. J Immunol. 2018 07 01; 201(1):124-133. PMID: 29752313.
      View in: PubMed
    14. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984.
      View in: PubMed
    15. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407. PMID: 29218851.
      View in: PubMed
    16. Verstovsek S, Fiskus W, Manshouri T, Bhalla KN. Targeting cistrome and dysregulated transcriptome of post-MPN sAML. Oncotarget. 2017 Nov 07; 8(55):93301-93302. PMID: 29212143.
      View in: PubMed
    17. Benton CB, Fiskus W, Bhalla KN. Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer. Cancer J. 2017 Sep/Oct; 23(5):286-291. PMID: 28926429.
      View in: PubMed
    18. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul 26; 18(8). PMID: 28933735.
      View in: PubMed
    19. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774.
      View in: PubMed
    20. Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018 02; 32(2):343-352. PMID: 28663582.
      View in: PubMed
    21. Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Res Treat. 2017 Sep; 165(2):375-382. PMID: 28623430.
      View in: PubMed
    22. Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018 01; 32(1):49-60. PMID: 28579617.
      View in: PubMed
    23. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922.
      View in: PubMed
    24. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2017 07; 31(7):1658. PMID: 28322226.
      View in: PubMed
    25. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 09; 31(9):1951-1961. PMID: 28042144.
      View in: PubMed
    26. Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528. PMID: 27927766.
      View in: PubMed
    27. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85a, androgen receptor, and Src. J Biol Chem. 2016 10 21; 291(43):22841. PMID: 27825079.
      View in: PubMed
    28. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687. PMID: 27677740.
      View in: PubMed
    29. Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN. SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. Cancer Res. 2016 09 15; 76(18):5467-78. PMID: 27503926.
      View in: PubMed
    30. Bhalla KN, Fiskus W. NEDD8 and HDACs: promising cotargets in AML. Blood. 2016 05 05; 127(18):2168-70. PMID: 27151736.
      View in: PubMed
    31. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2. PMID: 27210295.
      View in: PubMed
    32. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24; 126(13):1565-74. PMID: 26254443.
      View in: PubMed
    33. Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S. Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime ß-Catenin Pathway Inhibitors. J Med Chem. 2015 Aug 13; 58(15):5854-62. PMID: 26182238.
      View in: PubMed
    34. Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):587-95. PMID: 26210682.
      View in: PubMed
    35. Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. 2016 Feb; 30(2):504-8. PMID: 26148704.
      View in: PubMed
    36. Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel ß-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015 Jun; 29(6):1267-78. PMID: 25482131.
      View in: PubMed
    37. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Jul 30; 5(14):5637-50. PMID: 25026298.
      View in: PubMed
    38. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct; 13(10):2315-27. PMID: 25053825.
      View in: PubMed
    39. Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul; 146(1):145-52. PMID: 24903226.
      View in: PubMed
    40. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014 Nov; 28(11):2155-64. PMID: 24699304.
      View in: PubMed
    41. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla KN. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014 May 01; 74(9):2520-32. PMID: 24599128.
      View in: PubMed
    42. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 May; 13(5):1142-54. PMID: 24435446.
      View in: PubMed
    43. Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica. 2013 Oct; 98(10):1499-509. PMID: 24091929.
      View in: PubMed
    44. Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 2013 Dec; 33(12):1341-52. PMID: 23798029.
      View in: PubMed
    45. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 01; 19(13):3671-80. PMID: 23757357.
      View in: PubMed
    46. DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35. PMID: 23701016.
      View in: PubMed
    47. Yang Y, Fiskus W, Yong B, Atadja P, Takahashi Y, Pandita TK, Wang HG, Bhalla KN. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6841-6. PMID: 23569248.
      View in: PubMed
    48. Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013 May; 12(5):577-88. PMID: 23445613.
      View in: PubMed
    49. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013 Aug; 27(8):1628-36. PMID: 23385375.
      View in: PubMed
    50. Burns TA, Subathra M, Signorelli P, Choi Y, Yang X, Wang Y, Villani M, Bhalla K, Zhou D, Luberto C. Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene. J Lipid Res. 2013 Mar; 54(3):794-805. PMID: 23160178.
      View in: PubMed
    51. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13. PMID: 23174881.
      View in: PubMed
    52. Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 2012 Nov; 3(11):1416-27. PMID: 23232026.
      View in: PubMed
    53. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct 16; 22(4):506-523. PMID: 23079660.
      View in: PubMed
    54. Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res. 2012 Nov 15; 18(22):6227-38. PMID: 22932665.
      View in: PubMed
    55. Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. Role of additional novel therapies in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012 Oct; 26(5):959-80. PMID: 23009932.
      View in: PubMed
    56. Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat. 2012 Sep; 135(2):433-44. PMID: 22825030.
      View in: PubMed
    57. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8. PMID: 22460584.
      View in: PubMed
    58. Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012 Apr; 11(4):973-83. PMID: 22367781.
      View in: PubMed
    59. Walker SL, Ariga J, Mathias JR, Coothankandaswamy V, Xie X, Distel M, Köster RW, Parsons MJ, Bhalla KN, Saxena MT, Mumm JS. Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafish. PLoS One. 2012; 7(1):e29916. PMID: 22238673.
      View in: PubMed
    60. Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. HDAC inhibitors and chaperone function. Adv Cancer Res. 2012; 116:239-62. PMID: 23088873.
      View in: PubMed
    61. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JA. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2012 Apr; 132(3):1063-72. PMID: 22200869.
      View in: PubMed
    62. Ustun C, Savage NM, Gotlib J, Bhalla K, Manaloor E, George TI. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review. Am J Hematol. 2012 Feb; 87(2):191-3. PMID: 22081475.
      View in: PubMed
    63. Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011 Dec 01; 17(23):7347-58. PMID: 21976548.
      View in: PubMed
    64. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen L, Venkannagari S, Ha K, Abhyankar S, Williams C, McGuirk J, Khoury HJ, Ustun C, Bhalla KN. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood. 2011 Sep 15; 118(11):3096-106. PMID: 21719597.
      View in: PubMed
    65. Arellano M, Winton E, Pan L, Lima L, Tighiouart M, Bhalla K, Heffner LT, Neely J, Hutcherson D, McLemore M, Langston A, Khoury HJ. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer. 2012 Jan 15; 118(2):428-33. PMID: 21717443.
      View in: PubMed
    66. Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, Nalabothula NR, Bhalla KN. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther. 2011 Jul; 10(7):1194-206. PMID: 21566061.
      View in: PubMed
    67. Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, Burchert A, Szulc Z, Bielawska A, Ozato K, Bhalla K, Liu K. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 2011 Apr 15; 71(8):2882-91. PMID: 21487040.
      View in: PubMed
    68. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr 01; 186(7):3986-96. PMID: 21368229.
      View in: PubMed
    69. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5. PMID: 21098399.
      View in: PubMed
    70. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010 Dec 01; 120(12):4569-82. PMID: 21041953.
      View in: PubMed
    71. Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, Bhalla KN, Robertson KD. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet. 2011 Jan 01; 20(1):126-40. PMID: 20940144.
      View in: PubMed
    72. Choi JH, Li Y, Guo J, Pei L, Rauch TA, Kramer RS, Macmil SL, Wiley GB, Bennett LB, Schnabel JL, Taylor KH, Kim S, Xu D, Sreekumar A, Pfeifer GP, Roe BA, Caldwell CW, Bhalla KN, Shi H. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS One. 2010 Sep 29; 5(9). PMID: 20927367.
      View in: PubMed
    73. Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood. 2010 Dec 09; 116(24):5306-15. PMID: 20810927.
      View in: PubMed
    74. Rao R, Nalluri S, Fiskus W, Balusu R, Joshi A, Mudunuru U, Buckley KM, Robbins K, Ustun C, Reuther GW, Bhalla KN. Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells. Mol Cancer Ther. 2010 Aug; 9(8):2232-42. PMID: 20663926.
      View in: PubMed
    75. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res. 2010 Oct 01; 16(19):4742-54. PMID: 20647473.
      View in: PubMed
    76. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ß-phenylethyl isothiocyanate. Blood. 2010 Oct 14; 116(15):2732-41. PMID: 20566897.
      View in: PubMed
    77. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, Ha K, Buckley KM, Balusu R, Coothankandaswamy V, Joshi A, Atadja P, Bhalla KN. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):942-52. PMID: 20371724.
      View in: PubMed
    78. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010 Apr; 24(4):699-705. PMID: 20111068.
      View in: PubMed
    79. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 2010 Jan; 6(1):19-35. PMID: 20110775.
      View in: PubMed
    80. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009 Dec; 15(12):1369-76. PMID: 19966776.
      View in: PubMed
    81. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, Bhalla KN. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009 Dec 03; 114(24):5024-33. PMID: 19828702.
      View in: PubMed
    82. Ustun C, DeRemer DL, Jillella AP, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. Expert Opin Investig Drugs. 2009 Oct; 18(10):1445-56. PMID: 19671038.
      View in: PubMed
    83. Robertson KD, Bhalla KN. Missteps in "tango" for epigenome targeting. Blood. 2009 Sep 24; 114(13):2569-70. PMID: 19779044.
      View in: PubMed
    84. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol. 2009 Oct; 147(1):97-101. PMID: 19663825.
      View in: PubMed
    85. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009 Sep 24; 114(13):2733-43. PMID: 19638619.
      View in: PubMed
    86. Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther. 2009 Jul; 8(13):1273-80. PMID: 19440035.
      View in: PubMed
    87. Bhalla K, Naghavi M, Shahraz S, Bartels D, Murray CJ. Building national estimates of the burden of road traffic injuries in developing countries from all available data sources: Iran. Inj Prev. 2009 Jun; 15(3):150-6. PMID: 19494093.
      View in: PubMed
    88. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther. 2009 May; 8(10):939-50. PMID: 19279403.
      View in: PubMed
    89. Buckley K, Fiskus W, Bhalla K. Activation of mTOR: A new mechanism "PIMed". Cancer Biol Ther. 2009 May; 8(9):854-5. PMID: 19363296.
      View in: PubMed
    90. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009 May 19; 100(10):1523-9. PMID: 19401686.
      View in: PubMed
    91. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009 Apr 24; 284(17):11171-83. PMID: 19265193.
      View in: PubMed
    92. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, Bhalla KN. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009 Apr 23; 113(17):4038-48. PMID: 19074726.
      View in: PubMed
    93. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan; 10(1):92-100. PMID: 19011628.
      View in: PubMed
    94. Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009 May; 33(5):735-41. PMID: 18986703.
      View in: PubMed
    95. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008 Oct 01; 14(19):6106-15. PMID: 18829489.
      View in: PubMed
    96. Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 2008 Oct 01; 112(7):2896-905. PMID: 18660379.
      View in: PubMed
    97. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 2008 Sep 01; 112(5):1886-93. PMID: 18591380.
      View in: PubMed
    98. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, Atadja P, Bhalla K. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res. 2008 Jun 15; 68(12):4833-42. PMID: 18559531.
      View in: PubMed
    99. Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C, Winer E. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90. PMID: 18306034.
      View in: PubMed
    100. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res. 2008 Jun; 32(6):936-43. PMID: 18155764.
      View in: PubMed
    101. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 2007 Nov 15; 67(22):10744-52. PMID: 18006817.
      View in: PubMed
    102. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, Bhalla K, Bai W. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol. 2007 Nov; 9(11):1253-62. PMID: 17934453.
      View in: PubMed
    103. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9. PMID: 17900686.
      View in: PubMed
    104. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther. 2007 Sep; 6(9):2515-24. PMID: 17876048.
      View in: PubMed
    105. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15; 110(10):3540-6. PMID: 17715389.
      View in: PubMed
    106. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007 Aug 15; 13(16):4882-90. PMID: 17699868.
      View in: PubMed
    107. Khaki P, Bhalla P, Sharma P, Chawla R, Bhalla K. Epidemilogical analysis of Neisseria gonorrhoeae isolates by antimicrobial susceptibility testing, auxotyping and serotyping. Indian J Med Microbiol. 2007 Jul; 25(3):225-9. PMID: 17901639.
      View in: PubMed
    108. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007 May; 5(5):474-96. PMID: 17509252.
      View in: PubMed
    109. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr; 6(4):1400-5. PMID: 17431118.
      View in: PubMed
    110. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006 Dec; 5(12):3096-104. PMID: 17172412.
      View in: PubMed
    111. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 01; 12(19):5869-78. PMID: 17020995.
      View in: PubMed
    112. Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia. 2006 Nov; 20(11):1989-91. PMID: 16932346.
      View in: PubMed
    113. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35. PMID: 16899611.
      View in: PubMed
    114. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006 Jul 01; 66(13):6512-20. PMID: 16818622.
      View in: PubMed
    115. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51. PMID: 16775235.
      View in: PubMed
    116. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res. 2006 Apr 15; 66(8):4309-18. PMID: 16618756.
      View in: PubMed
    117. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006 Jul 15; 108(2):645-52. PMID: 16537804.
      View in: PubMed
    118. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006 May; 69(5):1527-33. PMID: 16436588.
      View in: PubMed
    119. Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV, Blagosklonny MV. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ. 2006 Sep; 13(9):1434-41. PMID: 16311509.
      View in: PubMed
    120. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005 Nov 15; 65(22):10536-44. PMID: 16288046.
      View in: PubMed
    121. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6. PMID: 16291594.
      View in: PubMed
    122. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):732-55. PMID: 16316611.
      View in: PubMed
    123. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005 Sep; 4(9):1311-9. PMID: 16170022.
      View in: PubMed
    124. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005 Sep 01; 11(17):6382-9. PMID: 16144943.
      View in: PubMed
    125. Swaby RF, Bhalla KN. Importance of rational pre-clinical development: gemcitabine comes of age. Cancer Biol Ther. 2005 Aug; 4(8):872-3. PMID: 16103749.
      View in: PubMed
    126. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005 Jul 22; 280(29):26729-34. PMID: 15937340.
      View in: PubMed
    127. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005 Jun 10; 23(17):3971-93. PMID: 15897549.
      View in: PubMed
    128. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005 Jan 15; 65(2):613-21. PMID: 15695406.
      View in: PubMed
    129. Bhalla K, List A. Histone deacetylase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec; 17(4):595-611. PMID: 15494297.
      View in: PubMed
    130. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005 Feb 15; 105(4):1768-76. PMID: 15514006.
      View in: PubMed
    131. Staley CA, Harris WB, Landry J, Small W, Kooby D, Gillespie TW, Meyers M, Bhalla KN. Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies. Surg Oncol Clin N Am. 2004 Oct; 13(4):697-709, x. PMID: 15350943.
      View in: PubMed
    132. Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 2005 Feb 01; 105(3):1135-43. PMID: 15454486.
      View in: PubMed
    133. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood. 2005 Feb 01; 105(3):1246-55. PMID: 15388581.
      View in: PubMed
    134. Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods. 2004 Sep; 292(1-2):59-71. PMID: 15350512.
      View in: PubMed
    135. Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 2004 Aug 01; 10(15):4991-7. PMID: 15297399.
      View in: PubMed
    136. Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem. 2004 Sep 17; 279(38):39431-7. PMID: 15262986.
      View in: PubMed
    137. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004 May 15; 64(10):3645-52. PMID: 15150124.
      View in: PubMed
    138. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004 Apr 01; 64(7):2580-9. PMID: 15059915.
      View in: PubMed
    139. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp. 2004; 259:249-66; discussion 266-8, 285-8. PMID: 15171259.
      View in: PubMed
    140. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003 Dec 08; 22(56):9075-86. PMID: 14663486.
      View in: PubMed
    141. Nimmanapalli R, Bali P, O'Bryan E, Fuino L, Guo F, Wu J, Houghton P, Bhalla K. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15; 63(22):7950-8. PMID: 14633726.
      View in: PubMed
    142. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003 Oct; 2(10):971-84. PMID: 14578462.
      View in: PubMed
    143. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003 Oct 31; 278(44):42992-3000. PMID: 12933816.
      View in: PubMed
    144. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003 Aug 15; 63(16):5126-35. PMID: 12941844.
      View in: PubMed
    145. Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol. 2003 Apr; 89(1):37-47. PMID: 12694652.
      View in: PubMed
    146. Yamaguchi H, Bhalla K, Wang HG. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res. 2003 Apr 01; 63(7):1483-9. PMID: 12670894.
      View in: PubMed
    147. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood. 2003 Jul 01; 102(1):269-75. PMID: 12623837.
      View in: PubMed
    148. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003 Jan 01; 63(1):93-9. PMID: 12517783.
      View in: PubMed
    149. Nimmanapalli R, Bhalla K. Targets in apoptosis signaling: promise of selective anticancer therapy. Methods Mol Biol. 2003; 223:465-83. PMID: 12777745.
      View in: PubMed
    150. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec 12; 21(57):8804-16. PMID: 12483533.
      View in: PubMed
    151. Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene. 2002 Dec 09; 21(56):8584-90. PMID: 12476305.
      View in: PubMed
    152. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 2003 Apr 15; 101(8):3236-9. PMID: 12446442.
      View in: PubMed
    153. Nimmanapalli R, Bhalla K. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol. 2002 Nov; 14(6):616-20. PMID: 12409651.
      View in: PubMed
    154. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002 Oct 15; 62(20):5761-9. PMID: 12384536.
      View in: PubMed
    155. Guo F, Bhalla K. The FLIP variation on the TRAIL DISC: doxorubicin conducts the swan song. Cancer Biol Ther. 2002 Sep-Oct; 1(5):528-9. PMID: 12496482.
      View in: PubMed
    156. Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, Jove R, Wu J. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia. 2002 Sep; 16(9):1589-95. PMID: 12200668.
      View in: PubMed
    157. Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. J Biol Chem. 2002 Aug 23; 277(34):30622-8. PMID: 12060665.
      View in: PubMed
    158. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O'Bryan E, Fumero C, Wang HG, Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood. 2002 May 01; 99(9):3419-26. PMID: 11964312.
      View in: PubMed
    159. O'Dwyer ME, La Rosée P, Nimmanapalli R, Bhalla KN, Druker BJ. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol. 2002 Apr; 39(2 Suppl 1):18-21. PMID: 12012318.
      View in: PubMed
    160. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 2002 Jan 15; 62(2):466-71. PMID: 11809697.
      View in: PubMed
    161. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 2001 Oct; 15(10):1537-43. PMID: 11587211.
      View in: PubMed
    162. Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 2001 May; 15(5):772-8. PMID: 11368438.
      View in: PubMed
    163. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001 Mar 01; 61(5):1799-804. PMID: 11280726.
      View in: PubMed
    164. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res. 2001 Feb; 7(2):350-7. PMID: 11234890.
      View in: PubMed
    165. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15; 61(2):759-63. PMID: 11212279.
      View in: PubMed
    166. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 2000 Dec 01; 96(12):3900-6. PMID: 11090076.
      View in: PubMed
    167. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000 Sep 15; 96(6):2246-53. PMID: 10979973.
      View in: PubMed
    168. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000 Mar 15; 60(6):1645-53. PMID: 10749135.
      View in: PubMed
    169. Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol. 2000 Feb; 74(3):1513-23. PMID: 10627563.
      View in: PubMed
    170. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000 Feb 01; 95(3):1014-22. PMID: 10648417.
      View in: PubMed
    171. Cai J, Zheng T, Masood R, Smith DL, Hinton DR, Kim CN, Fang G, Bhalla K, Gill PS. Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. Sarcoma. 2000; 4(1-2):37-45. PMID: 18521433.
      View in: PubMed
    172. Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999 Jul; 5(7):1723-30. PMID: 10430075.
      View in: PubMed
    173. Kim CN, Bhalla K, Kreitman RJ, Willingham MC, Hall P, Tagge EP, Jia T, Frankel AE. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res. 1999 Jun; 23(6):527-38. PMID: 10374846.
      View in: PubMed
    174. Han Z, Bhalla K, Pantazis P, Hendrickson EA, Wyche JH. Cif (Cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid. Mol Cell Biol. 1999 Feb; 19(2):1381-9. PMID: 9891071.
      View in: PubMed
    175. Burri SH, Kim CN, Fang G, Chang BS, Perkins C, Harris W, Davis LW, Thompson CB, Bhalla KN. 'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosis. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):423-30. PMID: 10030271.
      View in: PubMed
    176. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 1998 Dec 01; 17(23):6888-902. PMID: 9843495.
      View in: PubMed
    177. Ibrado AM, Kim CN, Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia. 1998 Dec; 12(12):1930-6. PMID: 9844922.
      View in: PubMed
    178. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 1998 Oct 15; 58(20):4561-6. PMID: 9788601.
      View in: PubMed
    179. Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 1998 Aug 01; 58(15):3202-8. PMID: 9699642.
      View in: PubMed
    180. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May; 16(5):1826-34. PMID: 9586897.
      View in: PubMed
    181. Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol. 1998 Apr; 25(2 Suppl 3):19-24. PMID: 9566203.
      View in: PubMed
    182. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998 Mar 01; 91(5):1700-5. PMID: 9473236.
      View in: PubMed
    183. Fontana JA, Sun RJ, Rishi AK, Dawson MI, Ordónez JV, Zhang Y, Tschang SH, Bhalla K, Han Z, Wyche J, Poirer G, Sheikh MS, Shroot B, Reichert U. Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid. Oncol Res. 1998; 10(6):313-24. PMID: 9848102.
      View in: PubMed
    184. Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1997 Nov 01; 90(9):3654-61. PMID: 9345050.
      View in: PubMed
    185. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G, Bhalla K. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 1997 Aug 01; 57(15):3115-20. PMID: 9242435.
      View in: PubMed
    186. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res. 1997 Mar 15; 57(6):1109-15. PMID: 9067280.
      View in: PubMed
    187. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997 Feb 21; 275(5303):1129-32. PMID: 9027314.
      View in: PubMed
    188. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 1997 Feb; 11(2):253-7. PMID: 9009089.
      View in: PubMed
    189. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat. 1997 Jan; 42(1):73-81. PMID: 9116321.
      View in: PubMed
    190. Ray S, Bullock G, Nuñez G, Tang C, Ibrado AM, Huang Y, Bhalla K. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 1996 Dec; 7(12):1617-23. PMID: 8959329.
      View in: PubMed
    191. Bullock G, Ray S, Reed JC, Krajewski S, Ibrado AM, Huang Y, Bhalla K. Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Leukemia. 1996 Nov; 10(11):1731-40. PMID: 8892676.
      View in: PubMed
    192. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 1996 Oct 15; 56(20):4743-8. PMID: 8840993.
      View in: PubMed
    193. Ibrado AM, Huang Y, Fang G, Bhalla K. Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ. 1996 Aug; 7(8):1087-94. PMID: 8853905.
      View in: PubMed
    194. Ponnathpur V, Ibrado AM, Reed JC, Ray S, Huang Y, Self S, Bullock G, Nawabi A, Bhalla K. Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. Clin Cancer Res. 1995 Nov; 1(11):1399-406. PMID: 9815937.
      View in: PubMed
    195. Bhalla K, Ibrado AM, Bradt JE, Ray S, Huang Y, Tang C, Nawabi A, Hoffman R. pIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells. Leukemia. 1995 Nov; 9(11):1851-6. PMID: 7475274.
      View in: PubMed
    196. Bullock G, Ray S, Reed J, Miyashita T, Maria Ibrado A, Huang Y, Bhalla K. Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells. Clin Cancer Res. 1995 May; 1(5):559-64. PMID: 9816016.
      View in: PubMed
    197. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos. 1995 Apr; 23(4):506-12. PMID: 7600920.
      View in: PubMed
    198. Kumar G, Ray S, Walle T, Huang Y, Willingham M, Self S, Bhalla K. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother Pharmacol. 1995; 36(2):129-35. PMID: 7767949.
      View in: PubMed
    199. Tang C, Huang Y, Ponnathpur VS, Ray S, Mahoney ME, Bullock G, Ibrado AM, Bhalla K. Combined antileukemic activity of pIXY 321 and Ara-C against human acute myeloid leukemia cells. Leuk Lymphoma. 1994 Nov; 15(5-6):445-51. PMID: 7874002.
      View in: PubMed
    200. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 1994 Nov; 8(11):1960-9. PMID: 7526093.
      View in: PubMed
    201. Liu Y, Bhalla K, Hill C, Priest DG. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol. 1994 Sep 15; 48(6):1265-72. PMID: 7945420.
      View in: PubMed
    202. Willingham MC, Bhalla K. Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J Histochem Cytochem. 1994 Apr; 42(4):441-50. PMID: 7907352.
      View in: PubMed
    203. Brandt JE, Bhalla K, Hoffman R. Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. Blood. 1994 Mar 15; 83(6):1507-14. PMID: 7510143.
      View in: PubMed
    204. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G, et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia. 1994 Mar; 8(3):465-75. PMID: 7907395.
      View in: PubMed
    205. Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, Bullock G, Bhalla K. 1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol. 1994; 34(5):365-71. PMID: 7915211.
      View in: PubMed
    206. Grant S, Baker M, Bhalla K. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report. Leukemia. 1993 Dec; 7(12):1933-8. PMID: 8255091.
      View in: PubMed
    207. Bullock G, Tang C, Tourkina E, Ibrado AM, Lutzky J, Huang Y, Mahoney ME, Bhalla K. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclo-phosphamide-induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol. 1993 Dec; 21(13):1640-7. PMID: 8243566.
      View in: PubMed
    208. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15; 82(10):3133-40. PMID: 8219202.
      View in: PubMed
    209. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 1993 Apr; 7(4):563-8. PMID: 8096557.
      View in: PubMed
    210. Bhalla K, Tourkina E, Huang Y, Tang C, Mahoney ME, Ibrado AM. Effect of hemopoietic growth factors G-CSF and pIXY 321 on the activity of high dose Ara-C in human myeloid leukemia cells. Leuk Lymphoma. 1993; 10 Suppl:123-31. PMID: 7683227.
      View in: PubMed
    211. Bhalla K, Tang C, Ibrado AM, Grant S, Tourkina E, Holladay C, Hughes M, Mahoney ME, Huang Y. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1992 Dec 01; 80(11):2883-90. PMID: 1450413.
      View in: PubMed
    212. Bhalla K, Bullock G, Lutzky J, Holladay C, Ibrado AM, Jasiok M, Singh S. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells. Leukemia. 1992 Aug; 6(8):814-9. PMID: 1640734.
      View in: PubMed
    213. Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells. Leukemia. 1992 May; 6(5):432-9. PMID: 1593908.
      View in: PubMed
    214. Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M, Singh S. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 1992 Apr; 45(1):32-9. PMID: 1601333.
      View in: PubMed
    215. Bhalla K, Swerdlow P, Grant S. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells. Blood. 1991 Dec 01; 78(11):2937-44. PMID: 1954383.
      View in: PubMed
    216. Bhalla K, Birkhofer M, Bhalla M, Lutzky J, Hindenburg A, Cole J, Ince C. A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. Am J Clin Oncol. 1991 Dec; 14(6):509-13. PMID: 1957839.
      View in: PubMed
    217. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood. 1991 Nov 15; 78(10):2674-9. PMID: 1824260.
      View in: PubMed
    218. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Safah H, Graham G. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells. Exp Hematol. 1991 Aug; 19(7):669-73. PMID: 1893953.
      View in: PubMed
    219. Grant S, Bhalla K, McCrady C. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Leuk Res. 1991; 15(4):205-13. PMID: 2030601.
      View in: PubMed
    220. Grant S, Bhalla K, Arlin Z, Howe CW. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture. Exp Hematol. 1990 Jan; 18(1):41-8. PMID: 2298268.
      View in: PubMed
    221. Bhalla K, Birkhofer M, Li GR, Grant S, MacLaughlin W, Cole J, Graham G, Volsky DJ. 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Blood. 1989 Nov 01; 74(6):1923-8. PMID: 2572282.
      View in: PubMed
    222. Hindenburg AA, Gervasoni JE, Krishna S, Stewart VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, Taub RN. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 1989 Aug 15; 49(16):4607-14. PMID: 2545346.
      View in: PubMed
    223. Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE, Rosado M, Stewart V, Krishna S, Hindenburg AA. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 1989 Aug 01; 49(15):4120-5. PMID: 2568167.
      View in: PubMed
    224. Bhalla K, Birkhofer M, Grant S, Graham G. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells. Exp Hematol. 1989 Jan; 17(1):17-20. PMID: 2783247.
      View in: PubMed
    225. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia. 1988 Dec; 2(12):810-3. PMID: 3264363.
      View in: PubMed
    226. Bhalla K, Birkhofer M, Grant S, Baker M, MacLaughlin W, Cole J, Graham G. Phase I clinical and pharmacologic study of deoxycytidine. Leukemia. 1988 Oct; 2(10):709-10. PMID: 3172847.
      View in: PubMed
    227. Bhalla K, Cole J, MacLaughlin W, Arlin Z, Baker M, Graham G, Grant S. Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells. Leukemia. 1987 Dec; 1(12):814-9. PMID: 2447450.
      View in: PubMed
    228. Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Blood. 1987 Aug; 70(2):568-71. PMID: 3607288.
      View in: PubMed
    229. Bhalla K, Grant S. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis. Cancer Chemother Pharmacol. 1987; 19(3):226-32. PMID: 3581416.
      View in: PubMed
    230. Bhalla K, Cole J, MacLaughlin W, Baker M, Arlin Z, Graham G, Grant S. Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1. Blood. 1986 Nov; 68(5):1136-41. PMID: 3464321.
      View in: PubMed
    231. Grant S, Bhalla K, Gleyzer M. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells. Leuk Res. 1986; 10(9):1139-46. PMID: 2429121.
      View in: PubMed
    232. Bhalla K, Hindenburg A, Taub RN, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res. 1985 Aug; 45(8):3657-62. PMID: 3860286.
      View in: PubMed
    233. Grant S, Bhalla K, Weinstein B, Pestka S, Mileno MD, Fisher PB. Recombinant human interferon sensitizes resistant myeloid leukemic cells to induction of terminal differentiation. Biochem Biophys Res Commun. 1985 Jul 16; 130(1):379-88. PMID: 3861180.
      View in: PubMed
    234. Grant S, Bhalla K, Gleyzer M. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis. Cancer Res. 1984 Dec; 44(12 Pt 1):5505-10. PMID: 6208998.
      View in: PubMed
    235. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res. 1984 Nov; 44(11):5029-37. PMID: 6091869.
      View in: PubMed
    236. Bhalla K, Nayak R, Deitch A, Grant S. Synergistic interaction between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Biochemical and cytokinetic considerations. Biochem Pharmacol. 1984 Jan 15; 33(2):247-54. PMID: 6200115.
      View in: PubMed
    237. Grant S, Bhalla K, Rauscher F, Cadman E. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60. Cancer Res. 1983 Nov; 43(11):5093-100. PMID: 6577943.
      View in: PubMed
    238. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Journal of Clinical Investigation. 120:4569-4582.
    239. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic myeloid progenitor cells.
    240. Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML. Cancer Biology and Therapy. 5:711.
    241. Importance of rational pre-clinical development. Cancer Biology and Therapy. 4.
    242. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia.
    243. Nucleophosmin (Npm1). 251-273.
    244. Differential effect of deoxycytidine on pyrimidine antagonist mediated growth suppression in normal versus leukemic human myeloid progenitor cells.
    245. Non-small-cell lung cancer adjuvant therapy. Oncology (Switzerland). 21:179-182.
    246. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. 30:504-508.
    247. Antitumor synergism between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Clinical Research. 30.
    248. NEDD8 and HDACs. Blood. 127:2168-2170.
    249. Overexpression of Bcl-xL inhibits ARA-C-induced mitochondrial perturbations that activate the molecular cascade of apoptosis. Experimental Hematology. 25:783.
    250. Erratum. Nature Immunology. 10:665.
    251. Potentiation of 6-thioguanine intracellular accumulation and cytotoxicity by methotrexate in L1210 cells.
    252. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia.
    253. Preferential enhancement of ara-C cytotoxicity by 2,3-dihydro-1H-imidazo [1,2-b] pyrazole (IMPY) in leukemic vs normal human myeloid progenitor cells.
    254. SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. Cancer Research. 76:5467-5478.
    BHALLA's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description